InsiderSignal.AI

InsiderSignal.ai

PTCT - Ptc Therapeutics, Inc.

Insider Sale by Boulding Mark Elliott (EVP, CLO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Boulding Mark Elliott, serving as EVP, CLO at Ptc Therapeutics, Inc. (PTCT), sold 2,265 shares at $69.45 per share, for a total transaction value of $157,293.00. Following this transaction, Boulding Mark Elliott now holds 105,212 shares of PTCT.

This sale represents a 2.00% decrease in Boulding Mark Elliott's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, April 6, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 8, 2026, 2 days after the trade was made.

Ptc Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Boulding Mark Elliott

EVP, CLO

# Mark Elliott Boulding Mark E. Boulding is the Executive Vice President and Chief Legal Officer (EVP and CLO) at PTC Therapeutics, Inc. (PTCT), a position he has held since March 2012.[[1]](https://www.ptcbio.com/team/leadership/mark-e-boulding/)[[2]](https://www.gurufocus.com/insider/64882/mark-elliott-boulding)[[6]](https://www.ptcbio.com/about-ptc/leadership/) He joined PTC in 2002 as Senior Vice President and General Counsel, advancing through his current role.[[1]](https://www.ptcbio.com/team/leadership/mark-e-boulding/) Boulding has been active in insider trading, including recent sales such as 4,033 shares on January 8, 2026, at $76.56 per share, and earlier transactions in 2025 totaling over $1.6 million, while owning approximately 103,901 to 113,626 shares valued at around $5-8.7 million.[[2]](https://www.gurufocus.com/insider/64882/mark-elliott-boulding)[[3]](https://www.investing.com/news/insider-trading-news/ptc-therapeutics-exec-vp-boulding-sells-16m-in-stock-93CH-4275986)[[4]](https://www.marketbeat.com/instant-alerts/ptc-therapeutics-nasdaqptct-vp-mark-elliott-boulding-sells-4033-shares-2026-01-12/)[[7]](https://www.quiverquant.com/news/Lobbying+Update:+$50,000+of+PTC+THERAPEUTICS+INC.+lobbying+was+just+disclosed) Prior to PTC, Boulding served as general counsel, executive vice president, and secretary at MedicaLogic/Medscape, and was a partner at two Washington, D.C.-based law firms, following experience at a New York-based law firm handling corporate and litigation matters.[[1]](https://www.ptcbio.com/team/leadership/mark-e-boulding/) He is involved in the Jumpstart New Jersey Angel Network, American Association for the Advancement of Science, American Bar Association, and Association of Corporate Counsel.[[1]](https://www.ptcbio.com/team/leadership/mark-e-boulding/)

View full insider profile →

Trade Price

$69.45

Quantity

2,265

Total Value

$157,293.00

Shares Owned

105,212

Trade Date

Monday, April 6, 2026

3 days ago

SEC Filing Date

Wednesday, April 8, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Ptc Therapeutics, Inc.

Company Overview

No company information available
View news mentioning PTCT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5474352

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime